RxDoctor Payments Data

Christopher Chien, MD

Advanced Heart Failure and Transplant Cardiology · Portland, ORNPI 1477732535

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $37,066 of the $57,328 with a category attached, or 64.7%. 14 manufacturers reported payments, led by Abbott at 54.4% of the total. Reporting peaked in 2022 at $14,338 and has fallen 61.7% since, to $5,490 in 2025.

$57,328in general payments, 2019–2025

Across 186 payments — averaging $308.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$31K
  • Boston Scientific$13K
  • Biotronik Inc.$8K
  • Cvrx, Inc.$2K
  • AstraZeneca$2K
  • Abiomed$762
  • plus $276 from 8 others
$1,380,623in research payments, 2019–2025

Across 90 payments — averaging $15,340 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • American Regent$916K
  • Abbott$299K
  • Boehringer Ingelheim$85K
  • AstraZeneca$68K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$12K
  • Boehringer Ingelheim Canada Ltd.ltee$281
  • plus $246 from 1 others

What the payments were for

  • Consulting fees$37,06665%
  • Travel & lodging$14,00424%
  • Food & beverage$6,24511%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott118$31,190
Boston Scientific12$13,121
Biotronik Inc.15$7,908
Cvrx, Inc.12$2,355
AstraZeneca6$1,716
Abiomed10$762
Novo Nordisk3$83
Novartis2$52
Pfizer2$37
Endotronix, Inc.1$27
Bayer1$26
Amgen2$25
Sensible Medical Innovations Inc1$19
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$7

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Oregonto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$30,366
Medicare patients
80
Services billed
291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan147$181,558
FarxigaDapagliflozin Propanediol51$50,165
EliquisApixaban41$47,466
JardianceEmpagliflozin23$32,011
Metoprolol Succinate143$2,725
Torsemide103$2,341
Spironolactone154$1,335
Potassium Chloride31$988
Amiodarone Hcl19$936
Atorvastatin Calcium48$643
Carvedilol59$481
Losartan Potassium64$401
Pravastatin Sodium17$368
Digoxin11$331
Rosuvastatin Calcium23$282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$52$181,558147 claims
AstraZenecaFarxiga$1,716$50,16551 claims
PfizerEliquis$37$47,46641 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Oregonon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →